ImmunoACT

In August 2024, The United States' Deputy Secretary of State for Management & Resources, Richard R Verma, spoke at the Centre for Social and Economic Progress (CSEP) about the collaborative efforts between the US & India, in highlighting India's first indigenous CAR-T cell therapy platform borne from Indian Institute of Technology, Bombay & Tata Memorial Centre that is today actualized by NexCAR19™, which received valuable guidance from the National Cancer Institute in Bethesda, MD. Click the link below, beginning 18:14 - https://lnkd.in/dvSTbCAu

At the Apollo Cancer Conclave 2024, NexCAR19 formed a prominent part of the discussions involving B-cell malignancies and their treatment in relapsed/refractory settings. Dr. Lingaraj Nayak, Professor of Medical Oncology (Adult Haematolymphoid Group) at TATA MEMORIAL HOSPITAL, delivered a "How I Treat" track presentation for B-cell acute lymphoblastic leukaemia (B-ALL), wherein NexCAR19's real-world snapshot was discussed. Dr. Padmaja Lokireddy's (Consultant Haematology & BMT, Apollo Hospitals, Jubilee Hills) presentation on treatment options in refractory/relapsed DLBCL also touched upon the optimal sequencing of CAR-T cell therapy for improving clinical outcomes. Dr. Gaurav Narula (Professor of Paediatric Oncology, Tata Memorial Centre) delivered a talk on the journey of NexCAR19 from ideation to the clinic and beyond. Dr. Navin Khattry (Dy. Director & Professor of Medical Oncology, Tata Memorial Centre) delivered a presentation on the use of Allo-SCT in the era of CAR-T cell therapy, elucidating further how these treatment options may fit in real-world settings. The haematolymphoid session also featured a keynote presentation by Dr. Nitin Jain from the MD Anderson Cancer Center, which highlighted their evolving treatment paradigm with CAR-T cell therapies in treating B-ALL. Our thanks to the organizers for providing us with an excellent academic platform for discussing how to provide comprehensive access to NexCAR19 to improve patients' clinical outcomes.

We’re #hiring ! To be a part of our journey, email your CV to jobs@immunoact.com We’re excited to connect with you!

We are pleased to announce that our first patient in Madhya Pradesh has been enrolled for treatment with NexCAR19™ at MGM Medical College's M.Y. Hospital in Indore. This is the latest milestone towards broadening access to our CAR-T cell therapies and aiming to improve overall survival outcomes in patients with relapsed/refractory B-cell cancers. It is also of note that this is the first government hospital in Central India to enroll a patient for treatment with NexCAR19™. https://lnkd.in/dkma-JRB

May the lights of Diwali fill your life with joy, prosperity, and happiness. Happy Diwali!! 🪔 🎉

We are pleased to announce a collaboration with SHALBY Sanar International Hospitals - to provide access to NexCAR19™, and our pipeline CAR-T cell therapies, at their state-of-the-art oncology treatment centres across India, another significant step in our goal of improving survival and quality of life in patients with B-ALL and B-NHL.

At the 19th International Conference of Drug Regulatory Authorities (ICDRA) held in New Delhi this week, following the theme of “Smart Regulation: Delivering Quality Assured Medical Products for All”, we showcased our fully integrated R&D and Manufacturing platform of CAR-T cell therapies, the first of which (NexCAR19™) was successfully market authorized in October 2023 and has since been infused in over 130 patients across India. We strive to achieve and maintain the highest quality and consistency in delivering our life-saving gene-modified cellular therapies, in an endeavour that focuses on adhering to global regulatory standards. Atharva Karulkar Manivasagam S

We’re #hiring ! To be a part of our journey, email your CV to jobs@immunoact.com and share your details with us on https://lnkd.in/dfWdWktc We’re excited to connect with you!

Happy Dussehra ! 🙏 Wishing you a joyful Dussehra filled with victory and joy!

Reminder: The latest in our webinar series begins in 1 hour, on the real-world experience of using NexCAR19™ in the treatment of relapsed/refractory B-NHLs and B-ALLs in adults and adolescents, from a real-world centre of excellence, by Dr. Prashant Mehta. Click the embedded link to join! https://lnkd.in/dxBTGEiw